secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK:        0000875320
Form:       8-K
Filed at:   2023-12-08T23:59:59+00:00
Accession:  0000875320-23-000054
Event type: regulatory
Sentiment:  positive
Materiality: 0.90
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA approves Vertex's CASGEVY gene therapy for sickle cell disease at $2.2M list price
--------------------------------------------------------------------------------

- On Dec 8, 2023, FDA approved CASGEVY (exagamglogene autotemcel) for sickle cell disease in patients 12+ with recurrent vaso-occlusive crises.
- Wholesale acquisition cost (WAC) set at $2.2 million.
- CASGEVY is an autologous genome edited hematopoietic stem cell-based gene therapy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875320/000087532023000054/0000875320-23-000054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875320/000087532023000054/vrtx-20231208.htm
  HTML page:      https://secwatch.observer/filing/0000875320-23-000054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer